Cubist Announces Objectives Met in Phase 2 Safety Study of CUBICIN in Prosthetic Joint Infections - News Press Release | PharmiWeb.com
Links shared publicly online about this topic.
- 1,023total visits
Cubist Announces Objectives Met in Phase 2 Safety Study of CUBICIN in Prosthetic Joint Infections - News Press Release | PharmiWeb.com
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST), a leading acute care therapeutics company, today announced that its Phase 2 safety study of CUBICIN (daptomycin for injection) in the treatment of prosthetic joint infections caused by certain Gra
View full resource at pharmiweb.com
Tags: Infection, Joint, Pharma, News, Safety
Most Recently Shared on July 14, 2010 at 12:02 pm By:
Press Release: Cubist Pharmaceuticals Inc. Posted on:14 Jul 10 Cubist Pharmaceuticals, Inc. http://bit.ly/d1itTs
Advertisement
